This pharmacoepidemiology study uses Medicare Part D data to describe changes in use of prescription drugs associated with an increase in fracture risk before and after fragility fractures.
This study examines the sharing, storage, and disposal of opioid medications by adults as well as the sources of information on those practices.
In a nationally representative sample of older adults, this study characterizes changes in the prevalence of medication use and quantifies the frequency and types of potential major drug-drug interactions.
This study evaluates the appropriateness of free-text notes added by prescribers in a nationally representative electronic prescribing system used in ambulatory care.
This Viewpoint discusses the implications of recent circuit court decisions regarding commercial speech and off-label marketing of prescription drugs.
This pharmacoepidemiology study assessed medication adherence before and after implementation of narrow insurance networks within commercial drug plans.
Austad and colleagues set out to determine whether there is an association between medical trainees’ interactions with pharmaceutical promotion and their preferences in medication use. Ross elucidates in the Editor’s Note.
Despite extensive use in practice, the impact of noninvasive cardiovascular imaging in primary prevention remains unclear.
We searched for randomized trials that compared imaging with usual care and reported any of the following outcomes in a primary prevention setting: medication prescribing, lifestyle modification (including diet, exercise, or smoking cessation), angiography, or revascularization.
Seven trials were included. Trials screened patients for inducible myocardial ischemia (2 trials), coronary calcification (3 trials), carotid atherosclerosis (1 trial), or left ventricular hypertrophy (1 trial). Imaging had no effect on medication prescribing overall (odds ratio [OR], 1.01; 95% confidence interval [CI], 0.76-1.33) or on provision of lipid-modifying agents (OR, 1.08; 95% CI, 0.58-2.01), antihypertensive drugs (OR, 1.05; 95% CI, 0.75-1.47), or antiplatelet agents (OR, 1.05; 95% CI, 0.84-1.32). Similarly, no effect was seen on dietary improvement (OR, 0.78; 95% CI, 0.22-2.85), physical activity (0.02 vs −0.08 point change for imaging vs control on a 5-point scale; P = .23), or smoking cessation (OR, 2.24; 95% CI, 0.97-5.19). Imaging was not associated with invasive angiography (OR, 1.26; 95% CI, 0.89-1.79).
We found limited evidence suggesting that noninvasive cardiovascular imaging alters primary prevention efforts. However, given the imprecision of these results, further high-quality studies are needed.